Literature DB >> 10348414

Bayesian estimation of cost-effectiveness ratios from clinical trials.

D F Heitjan1, A J Moskowitz, W Whang.   

Abstract

Estimation of the incremental cost-effectiveness ratio (ICER) is difficult for several reasons: treatments that decrease both cost and effectiveness and treatments that increase both cost and effectiveness can yield identical values of the ICER; the ICER is a discontinuous function of the mean difference in effectiveness; and the standard estimate of the ICER is a ratio. To address these difficulties, we have developed a Bayesian methodology that involves computing posterior probabilities for the four quadrants and separate interval estimates of ICER for the quadrants of interest. We compute these quantities by simulating draws from the posterior distribution of the cost and effectiveness parameters and tabulating the appropriate posterior probabilities and quantiles. We demonstrate the method by re-analysing three previously published clinical trials.

Mesh:

Year:  1999        PMID: 10348414     DOI: 10.1002/(sici)1099-1050(199905)8:3<191::aid-hec409>3.0.co;2-r

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  16 in total

Review 1.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

2.  Economic analysis of randomized, controlled trials.

Authors:  G H Lyman
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 3.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 5.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

7.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

8.  Cost effectiveness of abciximab during routine medical practice.

Authors:  S O Reed; C D Mullins; L S Magder
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

9.  Bayesian decision analysis for choosing between diagnostic/prognostic prediction procedures.

Authors:  John Kornak; Ying Lu
Journal:  Stat Interface       Date:  2011       Impact factor: 0.582

10.  Median-Based Incremental Cost-Effectiveness Ratio (ICER).

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Stat Theory Pract       Date:  2012-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.